TY - JOUR
T1 - Neuroprotection in Acute Ischemic Stroke
T2 - A Battle Against the Biology of Nature
AU - Ghozy, Sherief
AU - Reda, Abdullah
AU - Varney, Joseph
AU - Elhawary, Ahmed Sallam
AU - Shah, Jaffer
AU - Murry, Kimberly
AU - Sobeeh, Mohamed Gomaa
AU - Nayak, Sandeep S.
AU - Azzam, Ahmed Y.
AU - Brinjikji, Waleed
AU - Kadirvel, Ramanathan
AU - Kallmes, David F.
N1 - Funding Information:
The authors gratefully acknowledge the Scientific Publications staff at the Mayo Clinic for providing copyediting support.
Publisher Copyright:
Copyright © 2022 Ghozy, Reda, Varney, Elhawary, Shah, Murry, Sobeeh, Nayak, Azzam, Brinjikji, Kadirvel and Kallmes.
PY - 2022/5/31
Y1 - 2022/5/31
N2 - Stroke is the second most common cause of global death following coronary artery disease. Time is crucial in managing stroke to reduce the rapidly progressing insult of the ischemic penumbra and the serious neurologic deficits that might follow it. Strokes are mainly either hemorrhagic or ischemic, with ischemic being the most common of all types of strokes. Thrombolytic therapy with recombinant tissue plasminogen activator and endovascular thrombectomy are the main types of management of acute ischemic stroke (AIS). In addition, there is a vital need for neuroprotection in the setting of AIS. Neuroprotective agents are important to investigate as they may reduce mortality, lessen disability, and improve quality of life after AIS. In our review, we will discuss the main types of management and the different modalities of neuroprotection, their mechanisms of action, and evidence of their effectiveness after ischemic stroke.
AB - Stroke is the second most common cause of global death following coronary artery disease. Time is crucial in managing stroke to reduce the rapidly progressing insult of the ischemic penumbra and the serious neurologic deficits that might follow it. Strokes are mainly either hemorrhagic or ischemic, with ischemic being the most common of all types of strokes. Thrombolytic therapy with recombinant tissue plasminogen activator and endovascular thrombectomy are the main types of management of acute ischemic stroke (AIS). In addition, there is a vital need for neuroprotection in the setting of AIS. Neuroprotective agents are important to investigate as they may reduce mortality, lessen disability, and improve quality of life after AIS. In our review, we will discuss the main types of management and the different modalities of neuroprotection, their mechanisms of action, and evidence of their effectiveness after ischemic stroke.
KW - acute ischemic stroke
KW - ischemia
KW - management
KW - neuroprotection
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=85132375407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132375407&partnerID=8YFLogxK
U2 - 10.3389/fneur.2022.870141
DO - 10.3389/fneur.2022.870141
M3 - Review article
AN - SCOPUS:85132375407
SN - 1664-2295
VL - 13
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 870141
ER -